Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (211-220 of 239) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 3, 2026
Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium studyAngela Nolin, Morgan D Brown, Samantha M Thomas, et al.
Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III TrialJoyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neuAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 13, 2008
Cervical cancerBenjamin E Greer, Wui-Jin Koh, Nadeem Abu-Rustum, et al.
Pageof 24

Showing results (211-220 of 239) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 3, 2026
Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium studyAngela Nolin, Morgan D Brown, Samantha M Thomas, et al.
Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III TrialJoyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neuAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 13, 2008
Cervical cancerBenjamin E Greer, Wui-Jin Koh, Nadeem Abu-Rustum, et al.
Pageof 24